#USA #Canton #Kelyniam Global #cranial implants #Ross Bjella

Kelyniam Global Achieves Historic Milestones in 2024

Kelyniam Global, a prominent name in the manufacture of custom cranial implants, has unveiled its impressive financial results for the year ending December 31, 2024. The company, trading under the symbol KLYG on the OTC markets, experienced unparalleled growth in both revenue and profitability, marking what can be described as a historic year for the organization.

Strong Financial Performance

Kelyniam achieved total revenues of $3,328,382 during 2024, a significant increase of 24.6% from 2023's figures of $2,672,357. In a remarkable turnaround, the company reported operational income of $277,037, contrasting sharply with a loss of ($239,166) in the preceding year. Meanwhile, Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) reached $322,824, as opposed to an EBITDA loss of $189,758 recorded in 2023.

Ross Bjella, CEO of Kelyniam, expressed his satisfaction with the company's performance, stating, "Kelyniam had an exceptionally strong year in 2024. This marks the strongest performance in the company's history both financially and operationally." He credited these achievements to the dedicated efforts of the company’s strategic partners and the leadership of Desiree Webb, Vice President of Operations and Business Development. Webb’s adept management has facilitated the establishment of a skilled manufacturing team, providing timely and high-quality custom PEEK implants.

Key Events Influencing Performance

Several significant events contributed to Kelyniam's robust performance in 2024. Notably, the company successfully secured contracts with 15 new hospitals for the purchase of their implants. Additionally, wrapping up an FDA audit late last year resulted in five minor observations, all of which have been thoroughly addressed, reinforcing the trust in Kelyniam's operational standards.

In a progressive move, Kelyniam sponsored the Skull Base 360 wet lab at the University of Maryland, which has fostered and enhanced relationships with leading educational institutions in the medical field. This sponsorship not only showcases Kelyniam's commitment to education but also solidifies its position as a reputable player in cranial implant manufacturing.

Future Outlook

Looking ahead, Kelyniam aims to build on the achievements of 2024. The company plans to strengthen existing relationships with current partners while looking to in-license additional products to widen its offerings. A focus on organic growth will direct the company to invest significantly in sales and business development initiatives throughout 2025.

"We are well-positioned to partner with foreign entities involved in cranial surgery products, providing a vital distribution network and access to U.S. FDA-approved manufacturing facilities," stated Bjella. Kelyniam is thrilled about the future prospects and is dedicated to continuing its upward trajectory.

Kelyniam specializes in the rapid development of custom prosthetics, utilizing advanced technologies such as Computer-Aided Design (CAD) and Computer-Aided Manufacturing (CAM) to produce medical-grade polymer implants tailored for individual patients. This innovative approach allows Kelyniam to work closely with surgeons, health systems, and payors to enhance clinical and financial outcomes in medical care.

The intricate details of Kelyniam's financial performance and their strategic initiatives can be accessed via their official website at www.Kelyniam.com.

As a reminder to investors, it is crucial to recognize that certain statements included in this announcement are forward-looking, carrying inherent risks and uncertainties that could affect actual results. Such factors may include economic fluctuations, competitive pressures, and the company's ability to execute its operational plans effectively.

Overall, Kelyniam Global's performance in 2024 marks a significant turning point, projected to set new standards in customized medical solutions and operational excellence.